Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT.

Melanocortin 1 receptor (MC1R), a Gs protein-coupled receptor expressed in melanocytes, is a major determinant of skin pigmentation, phototype and cancer risk. Upon stimulation by αMSH, MC1R triggers the cAMP and ERK1/ERK2 MAPK pathways. In mouse melanocytes, ERK activation by αMSH binding to Mc1r depends on cAMP, and melanocytes are considered a paradigm for cAMP-dependent ERK activation. However, human MC1R variants associated with red hair, fair skin [red hair color (RHC) phenotype], and increased skin cancer risk display reduced cAMP signaling but activate ERKs as efficiently as wild type in heterologous cells, suggesting independent signaling to ERKs and cAMP in human melanocytes. We show that MC1R signaling activated the ERK pathway in normal human melanocytes and melanoma cells expressing physiological levels of endogenous RHC variants. ERK activation was comparable for wild-type and mutant MC1R and was independent on cAMP because it was neither triggered by stimulation of cAMP synthesis with forskolin nor blocked by the adenylyl cyclase inhibitor 2',5'-dideoxyadenosine. Stimulation of MC1R with αMSH did not lead to protein kinase C activation and ERK activation was unaffected by protein kinase C inhibitors. Conversely, pharmacological interference, small interfering RNA studies, expression profiles, and functional reconstitution experiments showed that αMSH-induced ERK activation resulted from Src tyrosine kinase-mediated transactivation of the stem cell factor receptor, a receptor tyrosine kinase essential for proliferation, differentiation, and survival of melanocyte precursors, thus demonstrating a functional link between the stem cell factor receptor and MC1R. Moreover, this transactivation phenomenon is unique because it is unaffected by natural mutations impairing canonical MC1R signaling through the cAMP pathway.

[1]  J. García-Borrón,et al.  Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen‐activated protein kinase pathways , 2009, FEBS letters.

[2]  V. Hearing,et al.  Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady‐state retention of mutant forms in the proximal golgi , 2009, Journal of cellular physiology.

[3]  A. Hachiya,et al.  Production of the soluble form of KIT, s-KIT, abolishes stem cell factor-induced melanogenesis in human melanocytes. , 2008, The Journal of investigative dermatology.

[4]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[5]  Xin-Yun Huang,et al.  When a G protein-coupled receptor does not couple to a G protein. , 2007, Molecular bioSystems.

[6]  V. Hearing,et al.  The Regulation of Skin Pigmentation* , 2007, Journal of Biological Chemistry.

[7]  D. Duffy,et al.  Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. , 2007, Human molecular genetics.

[8]  J. Hwang,et al.  [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. , 2007, Biochemical pharmacology.

[9]  Ido Amit,et al.  Regulation of MAPKs by growth factors and receptor tyrosine kinases. , 2007, Biochimica et biophysica acta.

[10]  Narasimhan P. Agaram,et al.  L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.

[11]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[12]  J. García-Borrón,et al.  Regulation of Human Melanocortin 1 Receptor Signaling and Trafficking by Thr-308 and Ser-316 and Its Alteration in Variant Alleles Associated with Red Hair and Skin Cancer* , 2007, Journal of Biological Chemistry.

[13]  N. Dhomen,et al.  New insight into BRAF mutations in cancer. , 2007, Current opinion in genetics & development.

[14]  Ping Chen,et al.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.

[15]  C. Springer,et al.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. , 2006, Cancer research.

[16]  D. Fisher,et al.  Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning , 2006, Nature.

[17]  D. Fisher,et al.  MITF: master regulator of melanocyte development and melanoma oncogene. , 2006, Trends in molecular medicine.

[18]  C. Liang,et al.  SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity , 2006, Molecular Cancer Therapeutics.

[19]  F. Lee,et al.  Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. , 2006, Blood.

[20]  F. Lozupone,et al.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.

[21]  J. Blenis,et al.  MAPK signal specificity: the right place at the right time. , 2006, Trends in biochemical sciences.

[22]  D. Rotin,et al.  The Guanine Nucleotide Exchange Factor CNrasGEF Regulates Melanogenesis and Cell Survival in Melanoma Cells* , 2006, Journal of Biological Chemistry.

[23]  R. Roskoski.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[24]  J. García-Borrón,et al.  Melanocortin-1 receptor structure and functional regulation. , 2005, Pigment cell research.

[25]  P. Parsons,et al.  Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells , 2005, Peptides.

[26]  N. Dumaz,et al.  Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways , 2005, The FEBS journal.

[27]  G. Babcock,et al.  alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. , 2005, Cancer research.

[28]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[29]  P. Sexton,et al.  ‘Ins and outs’ of seven-transmembrane receptor signalling to ERK , 2005, Trends in Endocrinology & Metabolism.

[30]  R. Roskoski,et al.  Src protein-tyrosine kinase structure and regulation. , 2004, Biochemical and biophysical research communications.

[31]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[32]  J. Rees,et al.  The genetics of sun sensitivity in humans. , 2004, American journal of human genetics.

[33]  S. Courtneidge,et al.  The interplay between Src family kinases and receptor tyrosine kinases , 2004, Oncogene.

[34]  D. Tobin,et al.  Melanin pigmentation in mammalian skin and its hormonal regulation. , 2004, Physiological reviews.

[35]  Carlos L Arteaga,et al.  Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? , 2004, Cancer cell.

[36]  Wei Chen,et al.  Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. , 2003, Human molecular genetics.

[37]  W. Hait,et al.  Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  J. Haycock,et al.  Anti-inflammatory and anti-invasive effects of α-melanocyte-stimulating hormone in human melanoma cells , 2003, British Journal of Cancer.

[39]  L. Guillo,et al.  Role of G protein-coupled receptor kinases in the homologous desensitization of the human and mouse melanocortin 1 receptors. , 2003, Molecular endocrinology.

[40]  K. Wakamatsu,et al.  Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. , 2003, Pigment cell research.

[41]  J. García-Borrón,et al.  Rate limiting factors in melanocortin 1 receptor signalling through the cAMP pathway. , 2003, Pigment cell research.

[42]  M. Shibuya,et al.  Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3)* , 2003, Journal of Biological Chemistry.

[43]  C. Hughes-Darden,et al.  Evidence for the interaction of protein kinase C and melanocortin 3-receptor signaling pathways , 2003, Neuropeptides.

[44]  R. Wetzker,et al.  Transactivation joins multiple tracks to the ERK/MAPK cascade , 2003, Nature Reviews Molecular Cell Biology.

[45]  U. Hellman,et al.  Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk. , 2003, Experimental cell research.

[46]  D. Bennett,et al.  The color loci of mice--a genetic century. , 2003, Pigment cell research.

[47]  B. Wehrle-Haller.  The role of Kit-ligand in melanocyte development and epidermal homeostasis. , 2003, Pigment cell research.

[48]  D. Duffy,et al.  The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. , 2003, Pigment cell research.

[49]  N. G. Martin,et al.  Genetic Association and Cellular Function of MC1R Variant Alleles in Human Pigmentation , 2003, Annals of the New York Academy of Sciences.

[50]  N. Hayward.  Genetics of melanoma predisposition , 2003, Oncogene.

[51]  J. Baselga,et al.  TACE is required for the activation of the EGFR by TGF‐α in tumors , 2003 .

[52]  O. Livnah,et al.  The pp60c‐Src inhibitor PP1 is non‐competitive against ATP , 2003, FEBS letters.

[53]  J. Haycock,et al.  Loss-of-function variants of the human melanocortin-1 receptor gene in melanoma cells define structural determinants of receptor function. , 2002, European journal of biochemistry.

[54]  J. Arbiser,et al.  Mitogen-actived protein kinase activation is an early event in melanoma progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  L. Kanter,et al.  Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  K. Devriendt,et al.  Human piebaldism: six novel mutations of the proto‐oncogene KIT , 2002, Human mutation.

[57]  In Hye Lee,et al.  Identification of Domains Directing Specificity of Coupling to G-proteins for the Melanocortin MC3 and MC4 Receptors* , 2002, The Journal of Biological Chemistry.

[58]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[59]  Shosuke Ito,et al.  Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. , 2002, Journal of cell science.

[60]  P. Stork,et al.  Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. , 2002, Trends in cell biology.

[61]  Z. Abdel‐Malek,et al.  Mitogen- and ultraviolet-B-induced signaling pathways in normal human melanocytes. , 2002, The Journal of investigative dermatology.

[62]  I. Jackson,et al.  Functional variation of MC1R alleles from red-haired individuals. , 2001, Human molecular genetics.

[63]  J. Gutkind,et al.  G-protein-coupled receptors and signaling networks: emerging paradigms. , 2001, Trends in pharmacological sciences.

[64]  M. Gishizky,et al.  SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling , 2000, Molecular and Cellular Biology.

[65]  R. Buscà,et al.  Ras mediates the cAMP‐dependent activation of extracellular signal‐regulated kinases (ERKs) in melanocytes , 2000, The EMBO journal.

[66]  J. Ramsden.  MARCKS: a case of molecular exaptation? , 2000, The international journal of biochemistry & cell biology.

[67]  R. Buscà,et al.  Cyclic AMP a key messenger in the regulation of skin pigmentation. , 2000, Pigment cell research.

[68]  I. Jackson,et al.  Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair , 2000, The Lancet.

[69]  L. Rönnstrand,et al.  Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. , 1999, The Biochemical journal.

[70]  S. Harrison,et al.  Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.

[71]  M. Maa,et al.  c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.

[72]  M. Tainsky,et al.  Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.

[73]  A. Brunet,et al.  Inhibition of the Mitogen-activated Protein Kinase Pathway Triggers B16 Melanoma Cell Differentiation* , 1998, The Journal of Biological Chemistry.

[74]  E. Price,et al.  MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes , 1998, Nature.

[75]  P. Beighton,et al.  Piebaldism with deafness: molecular evidence for an expanded syndrome. , 1998, American journal of medical genetics.

[76]  N. Martin,et al.  Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. , 1997, Human molecular genetics.

[77]  C. Wernstedt,et al.  Mutation of a Src phosphorylation site in the PDGF beta‐receptor leads to increased PDGF‐stimulated chemotaxis but decreased mitogenesis. , 1996, The EMBO journal.

[78]  A. Ullrich,et al.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.

[79]  W. Denny,et al.  Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. , 1996, Journal of medicinal chemistry.

[80]  J. Ortonne,et al.  Mitogen-activated Protein Kinase Pathway and AP-1 Are Activated during cAMP-induced Melanogenesis in B-16 Melanoma Cells (*) , 1995, The Journal of Biological Chemistry.

[81]  R. Halaban,et al.  Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[82]  S. Boyce,et al.  Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[83]  V. Swope,et al.  Contribution of melanogenic proteins to the heterogeneous pigmentation of human melanocytes. , 1993, Journal of cell science.

[84]  A. Ullrich,et al.  Progression of human cutaneous melanoma is associated with loss of expression of c‐kit proto‐oncogene receptor , 1992, International journal of cancer.

[85]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[86]  S. Lev,et al.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  E. Ingley,et al.  Src family kinases: regulation of their activities, levels and identification of new pathways. , 2008, Biochimica et biophysica acta.

[88]  E. Martínez-Alonso,et al.  Dimerization of the human melanocortin 1 receptor: functional consequences and dominant-negative effects. , 2006, The Journal of investigative dermatology.

[89]  R. Sturm.  Skin colour and skin cancer - MC1R, the genetic link. , 2002, Melanoma research.